The Cooper Companies, Inc. $COO Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. cut its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 8.7% during the third quarter, HoldingsChannel reports. The fund owned 405,770 shares of the medical device company’s stock after selling 38,780 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Cooper Companies were worth $22,938,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the business. Avalon Trust Co acquired a new stake in Cooper Companies during the second quarter worth $25,000. Elevation Wealth Partners LLC raised its position in Cooper Companies by 1,136.4% in the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 375 shares during the period. Continuum Advisory LLC purchased a new stake in Cooper Companies in the second quarter valued at $30,000. J.Safra Asset Management Corp purchased a new stake in Cooper Companies in the second quarter valued at $32,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new stake in Cooper Companies in the second quarter valued at $60,000. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Cooper Companies Stock Down 1.4%

Cooper Companies stock opened at $63.51 on Friday. The company has a market capitalization of $12.08 billion, a PE ratio of 21.68, a price-to-earnings-growth ratio of 2.53 and a beta of 0.83. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.73 and a current ratio of 1.22. The Cooper Companies, Inc. has a fifty-two week low of $51.01 and a fifty-two week high of $89.83. The firm has a 50 day moving average price of $59.37 and a 200 day moving average price of $68.70.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. The company had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.10 billion. During the same period in the prior year, the firm earned $0.49 earnings per share. The firm’s revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Research analysts expect that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies announced that its Board of Directors has initiated a share buyback program on Wednesday, September 9th that allows the company to buy back $3 billion in shares. This buyback authorization allows the medical device company to repurchase up to 22.7% of its shares through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

Several brokerages have recently commented on COO. Citigroup reaffirmed a “neutral” rating and issued a $60.00 price target (down from $80.00) on shares of Cooper Companies in a research note on Thursday, September 10th. Mizuho set a $75.00 price objective on Cooper Companies and gave the stock an “outperform” rating in a research report on Thursday, September 10th. Needham & Company LLC reduced their price objective on shares of Cooper Companies from $86.00 to $73.00 and set a “buy” rating on the stock in a report on Thursday, September 10th. Wall Street Zen lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. Finally, Bank of America cut shares of Cooper Companies from a “buy” rating to a “neutral” rating and decreased their target price for the company from $80.00 to $65.00 in a research report on Thursday, September 10th. Four equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $68.60.

Insider Activity

In other news, Director Walter M. Rosebrough, Jr. bought 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were purchased at an average price of $54.29 per share, with a total value of $162,870.00. Following the purchase, the director owned 20,000 shares in the company, valued at approximately $1,085,800. The trade was a 17.65% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Lawrence Kurzius bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were purchased at an average cost of $54.93 per share, for a total transaction of $549,300.00. Following the purchase, the director owned 31,099 shares in the company, valued at $1,708,268.07. This represents a 47.40% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 34,701 shares of company stock valued at $1,880,039. 2.08% of the stock is currently owned by corporate insiders.

Cooper Companies Company Profile

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women’s health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women’s health.